Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | THEO-260 |
| Synonyms | |
| Therapy Description |
THEO-260 is an oncolytic adenovirus that may induce lysis of tumor cells and cancer-associated fibroblasts, potentially resulting in decreased tumor growth (J Clin Oncol, 41, no. 16_suppl (2023) e14573, Ann Oncol (2023) 34 (suppl_2): S1166). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| THEO-260 | THEO 260|THEO260 | THEO-260 is an oncolytic adenovirus that may induce lysis of tumor cells and cancer-associated fibroblasts, potentially resulting in decreased tumor growth (J Clin Oncol, 41, no. 16_suppl (2023) e14573, Ann Oncol (2023) 34 (suppl_2): S1166). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07211659 | Phase II | THEO-260 | Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients (OCTOPOD-IP) | Not yet recruiting | USA | 0 |
| NCT06618235 | Phase Ib/II | THEO-260 | Trial of THEO-260 in Ovarian Cancer Patients (OCTOPOD) | Recruiting | GBR | 0 |